Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 18 sources · 6 days · First seen 15 days ago · Last updated 9 days ago

European authorization of Hopledo for Parkinson's disease

Overview

The European Commission and the European Medicines Agency (EMA) have authorized Hopledo, a modified-release oral formulation of levodopa/carbidopa, for the treatment of adult patients with Parkinson’s disease.

The therapy is specifically indicated for patients experiencing moderate to severe motor fluctuations that are not adequately controlled by existing oral regimens. The drug utilizes a single hard capsule containing both immediate-release granules and prolonged-release pellets to provide rapid onset and stable plasma concentrations.

Zambon, the developer of the therapy, noted that motor fluctuations affect approximately 80% of Parkinson’s patients within ten years of diagnosis. A gradual rollout of Hopledo in European markets is expected to begin in October 2026.

Entities

Zambon · European Medicines Agency · World Health Organization · European Research Council · Hopledo

Timeline

9 days ago

[HEALTH] 10 sources
Medical research advances in cancer and Parkinson's disease
Recent medical advancements include new research into cancer metabolism resistance, ERC-funded glioblastoma targeting via the TEPOV project, and EMA approval of a new Parkinson's disease therapy.
15 days ago

[HEALTH] 10 sources
European Commission authorizes Hopledo for Parkinson's disease
The European Commission has authorized Hopledo, a new modified-release oral treatment for Parkinson's disease motor fluctuations, with a planned European market rollout starting October 2026.

Sources

calabrianews.it · canaledieci.it · codirp.it · corcianonline.it · hjemmelavet.dk · ilpuntonotizie.it · ilsannioquotidiano.it · iltempo.it · kitesurfzone.pl · lacronaca24.it · lamilano.it · laragione.eu · lecodellitorale.it · mediapress24.it · notizie.it · quotidianodelsud.it · quotidianodibari.it · zerounotv.it